INTRODUCTION
============

Because human immunodeficiency virus (HIV)-infected persons survive longer as a result of combination highly active antiretroviral therapy (HAART), preventing age-related chronic diseases, including coronary heart disease (CHD), is critical to further extending survival. Mortality from non-AIDS-defining conditions currently accounts for one-half of total mortality in HIV-infected persons; the leading causes of mortality from non-AIDS-defining conditions include non-AIDS malignancy, non-AIDS infection, cardiovascular disease, which includes stroke and heart failure in addition to CHD, violence, and liver-related mortality \[[@R1]\]. Triant *et al*. reported that HIV-infected patients had 1.75 times the risk for acute myocardial infarction compared with non-HIV-infected patients, after adjusting for age, sex, race/ethnicity, hypertension, diabetes, and dyslipidemia, but not smoking \[[@R2]\]. HIV-infected persons are at high risk for CHD through multiple pathways. Previous studies have noted high prevalence of smoking (50%-70%) among HIV-infected persons \[[@R3]\]. In addition, HIV infection and antiretroviral therapy (ART) can cause or exacerbate dyslipidemia \[[@R4]\]. Finally, HIV infection itself, especially with low CD4^+^ counts, increases the risk for CHD independent of any effect on lipids \[[@R5]\].

Previously published findings of CHD risk factors in HIV-infected persons have been derived from facility-based cohort studies \[[@R6]\]. Yet HIV cohort studies, drawn primarily from urban-based HIV centers, have limited representativeness. For example, the racial and ethnic distributions of HIV-infected persons in cohort studies are not necessarily reflective of the HIV-infected population \[[@R7]\]. Population-based surveillance data can augment previously published findings of CHD risk factors from HIV cohort studies, and can assist health care providers and public health agencies in planning and evaluating programs that reduce CHD among HIV-infected persons. We describe CHD risk factors from a population-based survey of HIV-infected persons receiving care in Oregon.

MATERIALS AND METHODS
=====================

We used 2007-2008 Oregon data from the Medical Monitoring Project (MMP), a cross-sectional, population-based, surveillance system that assessed behaviors, clinical outcomes, and the quality of care for HIV-infected persons who received health care for their HIV infection \[[@R7]\]. MMP used a 3-stage probabilistic sampling design, comprising state, provider, and patient levels. HIV providers were identified through laboratory tests consistent with HIV care, including viral load and CD4^+^ counts. In Oregon, the MMP sample was augmented by inviting all patients cared for in rural facilities to participate. Participating patients were interviewed and their medical records were abstracted for a 12-month period preceding the interview date. For the 2007-2008 data collection cycles, 539 patients in Oregon participated; the overall unweighted participation rate was 52.8%.

We evaluated the presence of the following CHD risk factors: diagnosis of preexisting CHD, diabetes or hypertension; total cholesterol (TC) ≥240 mg/dL; high-density lipoprotein cholesterol (HDL) \<40 mg/dL; triglycerides ≥200 mg/dL; current smoking; and obesity, defined as body mass index \>30 kg/m^2^. Smoking was determined from patient interview; all other risk factors were abstracted from the medical record. For patients with preexisting CHD or diabetes, we determined the proportion who met a non-HDL target goal of \<130 mg/dL, in accordance with National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines \[[@R8]\]. The non-HDL, calculated by subtracting HDL from total cholesterol, was used because, in the presence of hypertriglyceridemia, non-HDL better correlates with CHD risk than does low-density lipoprotein cholesterol (LDL). (A non-HDL of \<130 mg/dL is comparable to an LDL of \<100 mg/dL; a non-HDL of \>160 mg/dL is comparable to LDL \>130 mg/dL.) We compared participants in an age group at higher risk for CHD (males ≥45 years and females ≥55 years), as defined by NCEP ATP III guidelines, with younger participants.

All analyses were weighted to account for the complex survey method and rural oversample. We compared differences between younger and older age groups with chi-square tests; a *P* value \<.05 was considered statistically significant.

RESULTS
=======

Among the 539 HIV-infected patients interviewed in 2007-2008, the mean age of the survey group was 45.5 years (range: 18-76 years). Interviews occurred a mean of 12.4 years after HIV diagnosis and, for 95% of the survey group currently taking ARTs, a mean of 10.2 years after initiation of ART.

For the entire survey group, 5% had a diagnosis of CHD; 11% had diabetes; and 28% had hypertension (Table **[1](#T1){ref-type="table"}**). Among the entire group, 6% had 2 diagnoses among CHD, diabetes, and hypertension, and 1% had all three of these conditions associated with increased cardiovascular risk. Current smoking was reported by 46%; college graduates were less likely to smoke compared with those with lesser education (21% versus 53%, respectively; *P*\<.0001). Obesity was present among 17%. TC, HDL, or triglycerides were available for 65% of the survey group. The mean values for TC and HDL were 183.9 mg/dL and 39.7 mg/dL, respectively. The triglycerides distribution was skewed to the right; median triglyceride level was 178 mg/dL. Nine percent had TC ≥240 mg/dL; 55% had HDL \<40 mg/dL; and 42% had triglycerides ≥200 mg/dL.

In bivariate analysis, compared with those in the younger age group, patients in the older age group were more likely to be male, be non-Hispanic white, have graduated from college, be currently taking antiretroviral therapy, and have undetectable viral load. For CHD risk factors, compared with those in the younger age group, patients in the older age group (males ≥45 years and females ≥55 years) had higher prevalence of CHD and hypertension diagnoses, but lower prevalence of smoking and obesity (Table **[1](#T1){ref-type="table"}**).

Among the 15% of the survey group with either preexisting CHD or diabetes, 42% had a non-HDL \<130 mg/dL; 21% had a non-HDL \>160 mg/dL. Current smoking was reported among 38% of those with preexisting CHD or diabetes.

DISCUSSION
==========

In this cross-sectional, population-based survey, we determined that Oregon HIV-infected persons had CHD risk factors notable for high rates of smoking and dyslipidemia, findings comparable to reports from HIV cohort studies \[[@R5],[@R6]\]. In the DAD study, a multinational collaboration of previously established cohorts, the prevalences of current smoking at baseline was 51.5% and total cholesterol ≥240 mg/dL was 22.2%, compared with 46% and 9%, respectively, in our study \[[@R6]\]. In DAD, the prevalences of previous cardiovascular disease (1.4%), hypertension (8.5%), and diabetes (2.5%) at baseline were lower than our study, likely because the median age in DAD at baseline was 39 years age, compared with the mean age of 45.5 years age in this study. In contrast, in the HIV Outpatient Study, a cohort study of HIV-infected patients receiving care at 10 U.S. HIV specialty clinics, with median age of 42 years at baseline, 49% had hypertension and 9% had diabetes at baseline; 55% were current or former smokers \[[@R5]\]. As some CHD risk factors are highly influenced by patient age, ongoing public health surveillance of risk factors in HIV-infected persons, through population-based surveys, can best monitor dynamic patterns of health.

Current smoking was \>2.5 times as prevalent among HIV-infected persons in Oregon (46%) compared with adults statewide (18%) \[[@R9]\]. Especially concerning was the high smoking prevalence among patients with preexisting CHD or diabetes, who are at highest risk for myocardial infarction and CHD death. Similar to other reports, we confirmed that smoking prevalence was inversely associated with education \[[@R10]\]. Although patients in the older age group were better educated, age differences in smoking prevalence persisted when stratified by education level (data not shown). Survivor bias, however, might have partly explained the lower smoking prevalence among older HIV-infected persons. We did not have information regarding the extent of smoking cessation counseling or treatment to assess to what extent smoking was adequately addressed in clinical settings. Our findings reinforce that intensive strategies to combat smoking and overcome barriers to quitting are needed for HIV-infected persons.

Participants in the Oregon MMP had lipid patterns characterized by low HDL and high triglycerides. We found 55% of Oregon HIV-infected persons had a HDL \<40 mg/dL and 42% had triglycerides ≥200 mg/dL, population estimates that were likely overstated because patients with dyslipidemia were more likely to have had lipid panels drawn over a 12 month period in this cross-sectional survey. Other studies in HIV-infected persons have similarly detected high prevalence of dyslipidemia, albeit with lower estimates of low HDL. In the HIV-HEART study, Reinsch *et al*. found 27.5% had low HDL and 39% had elevated triglycerides \[[@R11]\]; in the Swiss HIV cohort study, Glass *et al*. found 37.2% had low HDL and 35.7% had elevated triglycerides \[[@R12]\]. HDL decreases early in HIV infection and typically does not completely return to premorbid levels with viral suppression. Especially concerning was the prevalence of dyslipidemia among HIV-infected persons with preexisting CHD or diabetes. Fewer than one-half of patients with CHD or diabetes had a non-HDL \<130 mg/dL, the target goal; one-fifth had a non-HDL \>160mg/dL. Although we did not have information about dietary interventions or drug therapy to manage dyslipidemia, our findings reveal that lipid management among the highest-risk group for CHD was suboptimal.

Assisting HIV-infected persons in maintaining a healthy weight is especially relevant for younger persons, who had higher prevalence of obesity (23%). Overall, however, obesity was one-half as prevalent among Oregon HIV-infected persons (17%) compared with NHANES (34%) \[[@R13]\]. Weight loss from advanced HIV infection did not account for lower obesity; no association existed between obesity and viral load or CD4^+^ count (data not shown). Finally, we identified prevalences of preexisting heart disease, diabetes, and hypertension that, while divergent from some HIV cohort studies, were comparable to the U.S. adult population with similar age and sex distribution.

This study had certain limitations. First, the sampling frame for the study only included HIV-infected persons who had established care. Thus, the prevalences for diagnoses of CHD, diabetes, and hypertension might have been higher because persons with symptomatic disease might have been more likely to seek care and because persons in care were more likely to have been diagnosed for subclinical conditions. Second, as described previously, a high proportion of the survey group had missing lipid and BMI data. Lipid results were abstracted only during the 12-month surveillance period. If patients without lipid tests recorded were more likely to be judged at low risk for CHD by the clinician or more likely to have had desirable lipid results before the surveillance period, our estimates for the prevalence of dyslipidemia would have been high. Even if all the patients in this survey who had missing lipid data were assumed to have normal lipids, however, 1/4 to 1/3 of Oregon HIV-infected persons would have had dyslipidemia, a higher prevalence than the national adult population in the National Health and Nutrition Examination Survey \[[@R14]\]. Third, because we did not have blood pressure measurements, we were unable to individually calculate the Framingham risk score, which would have provided a more detailed assessment of CHD risk among this population. Risk prediction models, however, should be validated among HIV-infected persons because the Framingham risk score is considered to underestimate CHD risk among the HIV-infected population \[[@R15]\]. Finally, our survey was limited to Oregon HIV-infected persons, and findings might not necessarily apply to the national population.

CONCLUSIONS
===========

Our findings reinforce the need to aggressively assess and manage risk factors for CHD, particularly smoking and lipids, among the HIV-infected population. With increasing survival and years living with HIV infection, many will transition into age groups with greater prevalences of CHD and other medical conditions, such as hypertension and diabetes, which impose risk of CHD. Further prolonging survival among HIV-infected persons will increasingly be influenced by non-AIDS-defining conditions. Ongoing public health surveillance of health risk behaviors specific to HIV-infected persons is essential to further improving the health of this population. Our novel use of population-based surveillance data from MMP to evaluate CHD risk factors among HIV-infected persons might be adopted by other states and expanded nationally.
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Prevalence of Demographic and HIV Infection Characteristics, and CHD Risk Factors Among HIV-Infected Persons, by Age Risk Group --- Oregon, 2007-2008

                                           Number of Patients with Data Available   \% of Patients with Data Available Having Characteristic[\*](#T2F1){ref-type="table-fn"} (95% CI)   Younger Age Risk Group Males \<45 Yrs, Females\<55 Yrs % (95% CI) (n = 263)   Older Age Risk Group Males ≥45 Yrs, Females ≥55 Yrs % (95% CI) (n = 276)   Prevalence Ratio (Older Age Risk Group/Younger Age Risk Group)
  ---------------------------------------- ---------------------------------------- --------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------- -------------------------------------------------------------------------- ----------------------------------------------------------------
  **Demographic Characteristics**                                                                                                                                                                                                                                                                                                                
  Male                                     537                                      90 (87-92)                                                                                          82 (77-87)                                                                    98 (96-99)                                                                 1.2 (1.1-1.3)
  Self-identified homosexual orientation   537                                      60 (56-65)                                                                                          56 (49-63)                                                                    65 (58-71)                                                                 1.2 (1.0-1.4)
  Non-Hispanic white race                  536                                      75 (70-80)                                                                                          67 (57-75)                                                                    84 (79-88)                                                                 1.2 (1.1-1.4)
  College graduates                        538                                      19 (16-23)                                                                                          14 (9-18)                                                                     25 (19-31)                                                                 1.9 (1.2-2.8)
  **HIV Infection Characteristics**                                                                                                                                                                                                                                                                                                              
  Currently on antiretroviral therapy      508                                      95 (92-97)                                                                                          91 (86-95)                                                                    98 (97-100)                                                                1.1 (1.0-1.1)
  Viral load undetectable                  461                                      77 (73-81)                                                                                          68 (62-75)                                                                    85 (80-90)                                                                 1.2 (1.1-1.4)
  CD4^+^ count ≥500                        453                                      50 (45-55)                                                                                          47 (40-54)                                                                    53 (46-60)                                                                 1.1 (0.9-1.4)
  **CHD Risk Factors**                                                                                                                                                                                                                                                                                                                           
  Prior diagnosis of CHD                   539                                      5 (3-8)                                                                                             1 (0-2)                                                                       10 (6-14)                                                                  8.7 (2.6-29.1)
  Prior diagnosis of diabetes              539                                      11 (7-16)                                                                                           9 (1-17)                                                                      14 (9-18)                                                                  1.5 (0.6-3.8)
  Prior diagnosis of hypertension          539                                      28 (23-32)                                                                                          16 (11-20)                                                                    40 (34-47)                                                                 2.6 (1.8-3.6)
  Current smoking                          538                                      46 (41-51)                                                                                          54 (47-62)                                                                    38 (32-45)                                                                 0.7 (0.6-0.9)
  Current obesity (BMI ≥30)                449                                      17 (13-21)                                                                                          23 (17-29)                                                                    11 (6-15)                                                                  0.5 (0.3-0.7)
  TC ≥240 mg/dL                            343                                      9 (6-13)                                                                                            7 (2-11)                                                                      12 (7-17)                                                                  1.8 (0.8-3.8)
  HDL \<40 mg/dL                           345                                      55 (48-61)                                                                                          60 (50-70)                                                                    51 (43-58)                                                                 0.8 (0.7-1.1)
  Triglycerides ≥200 mg/dL                 301                                      42 (35-49)                                                                                          44 (31-57)                                                                    41 (33-49)                                                                 0.9 (0.7-1.3)

Note. CI, confidence interval; CHD, coronary heart disease; HDL, high-density lipoprotein; TC, total cholesterol; BMI, body mass index.

All data are weighted to state population data.
